local_hospital

Azienda Ospedaliera Universitaria Senese

Address
Strada Delle Scotte 14, 53100 Siena, Italy

Oncology and Immunotherapy

At Azienda Ospedaliera Universitaria Senese, clinical research in neoplasms focuses on difficult-to-treat cancers such as advanced melanoma, metastatic or unresectable melanoma, Merkel cell carcinoma, and advanced non-small cell lung cancer with KRAS G12C mutation. These studies are exploring new treatment strategies and combinations to improve outcomes for patients with limited options.

  • Testing new immunotherapy approaches for melanoma and Merkel cell carcinoma
  • Evaluating combination treatments for advanced NSCLC with KRAS G12C mutation
  • Assessing treatment effectiveness in cancers resistant to prior therapy

This research reflects a strong interest in improving cancer care through innovative immune-based therapies and targeted treatment combinations.

Infectious Diseases

The site also contributes to studies in bacterial infections and mycoses, with a focus on serious fungal diseases such as candidemia and invasive candidiasis. The goal is to compare new antifungal treatment approaches with established care to find safer and more effective options for adults with severe infection.

  • Developing improved treatment options for candidemia and invasive candidiasis
  • Comparing a new antifungal therapy with standard treatment
  • Supporting better management of serious fungal bloodstream infections

This area highlights the hospital’s role in advancing care for complex infectious diseases where timely and effective treatment is especially important.

Cardiovascular Research

In cardiovascular diseases, research is centered on heart failure with mildly reduced or preserved ejection fraction, particularly in patients who also have systemic inflammation. These trials are examining whether new anti-inflammatory treatment strategies can lower the risk of serious heart-related events and improve long-term outcomes.

  • Studying therapies for heart failure with HFmrEF and HFpEF
  • Evaluating whether reducing inflammation can improve cardiovascular outcomes
  • Testing new approaches to prevent cardiovascular death and worsening heart failure

This research area shows a clear focus on improving treatment for patients with chronic heart failure and related inflammatory risk.

Skin and Connective Tissue Diseases

The skin and connective tissue diseases portfolio includes studies in advanced melanoma, where investigators are assessing new combinations and administration methods to better support treatment delivery and effectiveness. These efforts aim to refine how modern cancer therapies are used in everyday care.

  • Exploring new ways to deliver melanoma treatment
  • Assessing whether treatment combinations can improve control of advanced disease
  • Supporting better options for patients with advanced skin cancer

At Azienda Ospedaliera Universitaria Senese, this field connects dermatologic oncology with broader efforts to improve outcomes in aggressive skin cancers.

Site Overview

assignment
226
connected trials
corporate_fare
123
sponsors
science
366
IMPs

Activity Indicator

Last 6 months

14
Trials started
-42% vs previous period.
24
Trials started 6–12 months ago
226
Total trials linked
Highly Active
trending_downDeclining-42%
3
2
3
4
1
1
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 5 of 25 therapeutic areas and 15 of 366 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years

Top 40 of 343 compounds, ranked by number of trials.

lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
109
Sponsors (total)
123
Active sponsors
74

Sponsor Network

Top 74 by active trials.

lock +73 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +32 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 566 other sites in Italy

description
Trial volume
226
Outperforms 94% of sites
public
Therapeutic diversity
25areas
Outperforms 97% of sites
groups
Sponsor diversity
123sponsors
Outperforms 95% of sites

Therapeutic Area Benchmark — Italy

Select a therapeutic area to compare against other sites in Italy.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Italy

Market Share

Country: Italy

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Azienda Ospedaliera Universitaria Senese

lock Showing 1 of 226 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
"APalutamide and stEReotactic body radiation therapy for low burden metastatic hormone senSItive prostate cancer, a rANdomized trial -PERSIAN".Fondazione Radioterapia Oncologica OnlusPhase IIRecruitingMar 2023

IMP list

lock Showing 1 of 366 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Pembrolizumab34Unknown2015-07-162026-03-16

Request feasibility information

Ask this centre about capacity, equipment and patient population.

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.